Letter to the Editor: The Role of Skin Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity

Author:
Philip R. Cohen Department of Dermatology, University of California, Davis Medical Center, Sacramento, California; and
Touro University California College of Osteopathic Medicine, Vallejo, California

Search for other papers by Philip R. Cohen in
Current site
Google Scholar
PubMed
Close
 MD
Restricted access
  • Collapse
  • Expand
  • 1.

    Fecher LA, Bishu S, Fontana RJ, et al. The role of tissue biopsy in the management of immune checkpoint inhibitor toxicity. J Natl Compr Canc Netw 2022;20:417425.

  • 2.

    Park BC, Jung S, Chen ST, et al. Challenging dermatologic considerations associated with immune checkpoint inhibitors. Am J Clin Dermatol. Published online June 16, 2022. doi: 10.1007/s40257-022-00706-y

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 2020;83:12551268.

  • 4.

    Ellis SR, Vierra AT, Millsop JW, et al. Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features. J Am Acad Dermatol 2020;83:11301143.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Muntyanu A, Netchiporouk E, Gerstein W, et al. Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management. J Cutan Med Surg 2021;25:5976.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2384 232 4
PDF Downloads 313 99 17
EPUB Downloads 0 0 0